Amgen Inc. (NASDAQ: AMGN) delivered a strong earnings report on Aug. 4. AMGN stock rose approximately 17% from the Aug. 4 close through early September before reversing sharply.
One of the highlights of Amgen’s report was Repatha, Amgen's approved PCSK9 drug, which posted $953 million in Q2 2026 revenue, a 37% year-over-year increase. But those gains have mostly been erased due to what can only be labeled as guilt by association.